Servier Breaks Up With Pharmacyclics, Leaving Future Uncertain
This article was originally published in The Pink Sheet Daily
Pharmacyclics and Servier decided to just be friends, leaving the biotech on the hook for the development of the mid-stage HDAC inhibitor abexinostat.
You may also be interested in...
Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.